Matrix metalloproteinase inhibitors: A structure-activity study

被引:153
作者
Levy, DE
Lapierre, F
Liang, WS
Ye, WQ
Lange, CW
Li, XY
Grobelny, D
Casabonne, M
Tyrrell, D
Holme, K
Nadzan, A
Galardy, RE
机构
[1] Glycomed Inc, Dept Chem, Alameda, CA 94501 USA
[2] Glycomed Inc, Dept Biochem, Alameda, CA 94501 USA
关键词
D O I
10.1021/jm970494j
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Modifications around the dipeptide-mimetic core of a hydroxamic acid based matrix metalloproteinase inhibitor were studied. These variations incorporated a variety of natural, unnatural, and synthetic amino acids in addition to modifications of the P1' and P3' substituents. The results of this study indicate the following structural requirements: (1) Two key hydrogen bonds must be present between the enzyme and potent substrates. (2) Potent inhibitors must possess strong zinc-binding functionalities. (3) The potential importance of the hydrophobic group at position R3 as illustrated by its ability to impart greater relative potency against stromelysin when larger hydrophobic groups are used. (4) Requirements surrounding the nature of the amino acid appear to be more restrictive for stromelysin than for neutrophil collagenase, 72 kDa gelatinase, and 92 kDa gelatinase. These requirements may involve planar fused-ring aryl systems and possibly hydrogen-bonding capabilities.
引用
收藏
页码:199 / 223
页数:25
相关论文
共 55 条
[1]  
ACOSTA CK, 1991, J CHEM RES-S, P110
[2]   Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis [J].
Ahrens, D ;
Koch, AE ;
Pope, RM ;
SteinPicarella, M ;
Niedbala, MJ .
ARTHRITIS AND RHEUMATISM, 1996, 39 (09) :1576-1587
[3]   STROMELYSIN-1 - 3-DIMENSIONAL STRUCTURE OF THE INHIBITED CATALYTIC DOMAIN AND OF THE C-TRUNCATED PROENZYME [J].
BECKER, JW ;
MARCY, AI ;
ROKOSZ, LL ;
AXEL, MG ;
BURBAUM, JJ ;
FITZGERALD, PMD ;
CAMERON, PM ;
ESSER, CK ;
HAGMANN, WK ;
HERMES, JD ;
SPRINGER, JP .
PROTEIN SCIENCE, 1995, 4 (10) :1966-1976
[4]   Determination of metalloproteinases, plasminogen-activators and their inhibitors in the synovial fluids of patients with rheumatoid arthritis during chemical synoviorthesis [J].
Blaser, J ;
Triebel, S ;
Maasjosthusmann, U ;
Romisch, J ;
KrahlMateblowski, U ;
Freudenberg, W ;
Fricke, R ;
Tschesche, H .
CLINICA CHIMICA ACTA, 1996, 244 (01) :17-33
[5]  
BORKAKOTI N, 1994, STRUCT BIOL, V1, P106
[6]  
Buisson AC, 1996, LAB INVEST, V74, P658
[7]  
Buisson AC, 1996, J CELL PHYSIOL, V166, P413, DOI 10.1002/(SICI)1097-4652(199602)166:2<413::AID-JCP20>3.0.CO
[8]  
2-A
[9]   Phosphinic acid inhibitors of matrix metalloproteinases [J].
Caldwell, CG ;
Sahoo, SP ;
Polo, SA ;
Eversole, RR ;
Lanza, TJ ;
Mills, SG ;
Niedzwiecki, LM ;
IzquierdoMartin, M ;
Chang, BC ;
Harrison, RK ;
Kuo, DW ;
Lin, TY ;
Stein, RL ;
Durette, PL ;
Hagmann, WK .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1996, 6 (03) :323-328
[10]   NOVEL INDOLACTAM-BASED INHIBITORS OF MATRIX METALLOPROTEINASES [J].
CASTELHANO, AL ;
BILLEDEAU, R ;
DEWDNEY, N ;
DONNELLY, S ;
HORNE, S ;
KURZ, LJ ;
LIAK, TJ ;
MARTIN, R ;
UPPINGTON, R ;
YUAN, ZY ;
KRANTZ, A .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1995, 5 (13) :1415-1420